Philadelphia Inquirer Profiles CEO of Biosyn, Company’s Efforts To Develop Microbicide To Prevent STDs, Including HIV
The Philadelphia Inquirer on Monday profiled Anne-Marie Corner, president and CEO of Huntington, Pa.-based biotechnology firm Biosyn, which is working to develop a vaginal microbicide to prevent sexually transmitted diseases, including HIV/AIDS. Corner is overseeing the final development of Savvy, a microbicide that is expected to be on the market in 2007 (McCullough, Philadelphia Inquirer, 1/3). Microbicides include a range of products -- such as gels, films, sponges and other products -- that could help prevent the sexual transmission of HIV and other STDs (Kaiser Daily HIV/AIDS Report, 11/9/04). In the fall of 2004, Corner sold the rights to Savvy to Cellegy Pharmaceuticals, a Calif.-based biotechnology company. The microbicide is currently undergoing final human testing in Ghana, Nigeria and the United States (Philadelphia Inquirer, 1/3). The complete article, which profiles nine other leaders in health and biotechnology in the Philadelphia area, is available online.This is part of the KHN Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.